8-K filing — Roivant Sciences Ltd. (ROIV)
Filed: 2026-08-28 AccNo: 0001140361-26-034854 Size: 2 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
FDA Clears First Targeted Dermatomyositis Treatment From Roivant
FDA approves Roivant's LISRAYA for adult dermatomyositis, offering a once-daily targeted therapy that reduces steroid dependency.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $41 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $41 price target.
Roivant's Priovant Says FDA Approved LISRAYA For Dermatomyositis In Adults, First Targeted Therapy For The Disease; Available In U.S. Immediately